FTD Science Digest – Collaboration for Future FTD Clinical Trials: the 2025 FTD Research Roundtable
This September marked the third annual FTD Research Roundtable hosted by AFTD. This event brings together diverse stakeholders, particularly industry partners, working towards addressing barriers to finding disease-modifying therapies for FTD. Each year is focused on a new topic. This year’s title was “outcome measures and statistical power in FTD clinical trials,” which are important…
Read MoreMeet the Researcher: Indira García-Cordero, PhD
“Over the years, I have had the privilege of meeting and working with people living with FTD and their families. Their strength and resilience have inspired me and motivated me to focus my research on this area. Through my work, I hope to give something back by improving our understanding of the disease. I am…
Read MoreFTD Research Spotlight – Collaboration for Future FTD Clinical Trials: the 2025 FTD Research Roundtable
This September marked the third annual FTD Research Roundtable hosted by AFTD. This event brings together diverse stakeholders, particularly industry partners, working towards addressing barriers to finding disease-modifying therapies for FTD. Each year is focused on a new topic. This year’s title was “outcome measures and statistical power in FTD clinical trials,” which are important…
Read MoreNew Recommendation: Expanding Genetic Counseling and Testing for People Diagnosed with FTD
The FTD genetic research landscape is evolving at an unprecedented pace. Although most FTD cases do not have a hereditary component, numerous clinical trials are now targeting gene-specific treatments, areas where researchers have developed stronger insights into potential therapeutic approaches. Understanding whether FTD has a genetic basis has become more crucial than ever—for those affected,…
Read MoreA Rose with Pink Petals: How FTD Revealed Deb Jobe’s Hidden Artist
Deb Jobe, co-chair of the AFTD Persons with FTD Advisory Council, was featured in the journal Brain & Life for the blooming of her artistic ability alongside FTD symptoms. Jobe never imagined she could draw. For years, her attempts produced nothing more than stick figures—the kind that would make a kindergartener cringe. Ask her husband…
Read MoreAlector Clinical Trial Results Townhall
On October 21, 2025, results from Alector Therapeutics’ Phase 3 clinical trial for Latozinemab (AL001) were announced. This intervention, designed for people with FTD caused by variants in the GRN gene, did not have an impact on clinical symptoms nor on a number of other endpoints. We know many people have questions and concerns about…
Read More
